We have started a clinical trial with a new antidiskinetic therapy (combination of two drugs already authorized in other indications) to evaluate its safety and efficacy in patients with severe dyskinesia in advanced Parkinson’s disease. The aim is to study a safer therapy and with a lower risk than the invasive therapies currently used .
